Business

Biogen Idec seeks OK for hemophilia B treatment

Biogen Idec Inc. has applied to the Food and Drug Administration for approval to market a new treatment for hemophilia B, the Weston biotechnology company said Friday.

Hemophilia B is a rare inherited disease that keeps patients’ blood from clotting and can cause bleeding, joint damage, and life-threatening hemorrhages. Biogen Idec said it submitted its biologics license application to the FDA recently and expects a decision some time this year. It is the first product in a class of clotting therapies the company is developing.

Advertisement

Biogen Idec said it is on track to submit a similar application for a drug to treat another form of the disease, hemophilia A, in the first quarter of this year.

The company, a global leader in multiple sclerosis drugs, said Thursday it was ending development of an experimental drug for Lou Gehrig’s disease after the drug proved ineffective in a late-phase clinical trial.

Robert Weisman

Robert Weisman can be reached at weisman@globe.com.
Loading comments...
Real journalists. Real journalism. Subscribe to The Boston Globe today.
You're reading  1 of 5 free articles.
Get UNLIMITED access for only 99¢ per week Subscribe Now >
You're reading1 of 5 free articles.Keep scrolling to see more articles recomended for you Subscribe now
We hope you've enjoyed your 5 free articles.
Continue reading by subscribing to Globe.com for just 99¢.
 Already a member? Log in Home
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of BostonGlobe.com
Marketing image of BostonGlobe.com